CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Islet Cell Transplantation for Patients with Unstable or Uncontrollable Diabetes Mellitus: Clinical Effectiveness, Cost-Effectiveness and Guidelines

Last updated: March 18, 2020
Project Number: RA1093-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of islet cell transplantation in patients with unstable diabetes mellitus?
  2. What is the cost-effectiveness of using islet cell transplantation in patients with unstable diabetes mellitus?
  3. What are the evidence-based guidelines associated with the use of islet cell transplantation in patients with unstable diabetes mellitus?

Key Message

Three health technology assessments, one randomized controlled trial, and three non-randomized studies were identified regarding the clinical effectiveness of islet cell transplantation in patients with unstable diabetes mellitus. In addition, one economic evaluation was identified regarding the cost-effectiveness of using islet cell transplantation in patients with unstable diabetes mellitus. Lastly, one evidence-based guideline associated with the use of islet cell transplantation in patients with unstable diabetes mellitus was identified.